Category: BioTech

Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Rumors Suggest Surprising Possibility of Valeant and Actavis Combination

Media reports over the weekend suggested Valeant Pharmaceuticals VRX held merger discussions with Actavis ACT , which may now have stalled on financial considerations. Valeant had been signaling that it was seeking to pursue a large acquisition or a merger of equals, so the magnitude of the deal was not surprising, but we were a little surprised by the target. Overall, there may be enough … Continue reading Rumors Suggest Surprising Possibility of Valeant and Actavis Combination

John MeadyLeave a comment
BioTech, Finance

Biotech News: Top Stocks Review For The Week

The trading session has ended on a higher note as the Dow Jones Industrial Average finished at 16,569.98, up 0.10% and the NASDAQ Composite closed at 4,401.33, up 0.70%. The S&P 500 finished the day 0.28% higher at 1,936.92. During the trading session seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 700.04, … Continue reading Biotech News: Top Stocks Review For The Week

Richard Atkins
Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

White Mountains’ Underwriting Margins Drive 1Q Book Value Increase

A benign catastrophe season and continued improvement in underwriting margins at majority-owned OneBeacon OB led to a 3% sequential increase in adjusted book value to $606 per share at White Mountains Insurance Group WTM . In comparison with last year’s first quarter, the combined ratio (expense divided by earned premiums) fell to 81% from 84% at Sirius Group, White Mountains’ reinsurance subsidiary, while OneBeacon also … Continue reading White Mountains’ Underwriting Margins Drive 1Q Book Value Increase

John MeadyLeave a comment
BioTech, Finance

Active Biotech Stock: A Look at Mannkind Corp

Shares of MannKind Corp. have been on a wild ride over the past year. Most of this volatility is the result of emotionally-charged retail investors pushing the stock past realistic valuation levels. This stock serves as another glaring example as to why it’s generally a bad idea to follow the crowd when investing in biotech stocks. MannKind Corp. (NASDAQ MNKD) is the latest cult biotech … Continue reading Active Biotech Stock: A Look at Mannkind Corp

Richard Atkins
FB Nasdaq FB Facebook
Analysis, BioTech, Diversified Tech, Finance, Mergers & Acquisitions, Semiconductors, Services Sector, software, Software, Tech IPO

Growing Competition on the Cotai Strip Leads to a Bad Quarterly Hand for Wynn Resorts

Wynn Resorts WYNN reported weak first-quarter results, as the company continued to perform poorly in Macau due to intensifying competition from new casinos on the Cotai Strip. Revenue and EBITDA were above consensus estimates, but only because the company had an unusually high hold rate for VIP table games in Macau and table games in Las Vegas. Revenue increased 5% to $1.38 billion (compared to … Continue reading Growing Competition on the Cotai Strip Leads to a Bad Quarterly Hand for Wynn Resorts

John MeadyLeave a comment
Gilead Sciences GILD NASDAQ:GILD
Analysis, BioTech, Commodities, Diversified Tech, Finance, Global Equity, Mergers & Acquisitions, Semiconductors, Services Sector, Software, software, Tech IPO

Strong Lumber and Panel Prices Buoy Weyerhaeuser’s 1Q; Deferred Harvests Causing Log Prices to Lag

Positive momentum in the long-suffering wood products business led improved results in Weyerhaeuser’s WY first quarter, as the segment benefited from improved housing demand and a cautious lumber industry that hasn’t fully recalibrated supply to meet the new demand reality. Results were more tepid in Weyerhaeuser’s other segments, as log prices haven’t enjoyed the kind of surge we’ve seen in lumber and panel prices, homebuilding … Continue reading Strong Lumber and Panel Prices Buoy Weyerhaeuser’s 1Q; Deferred Harvests Causing Log Prices to Lag

John MeadyLeave a comment